Rare variants in XRCC2 as breast cancer susceptibility alleles

Journal of Medical Genetics

Volumn 49, Issue 10, 2012, Pages 618-620

  Hilbers, Florentine S ^a   Wijnen, Juul T ^a   Hoogerbrugge, Nicoline ^b   Oosterwijk, Jan C ^c   Collee, Margriet J ^d   Peterlongo, Paolo ^e,f   Radice, Paolo ^e,f   Manoukian, Siranoush ^f   Feroce, Irene ^g   Capra, Fabio ^e,h   Couch, Fergus J ⁱ   Wang, Xianshu ⁱ   Guidugli, Lucia ⁱ   Offit, Kenneth ^j   Shah, Sohela ^j   Campbell, Ian G ^k,l   Thompson, Ella R ^k,l   James, Paul A ^k,l   Trainer, Alison H ^k,l   Gracia, Javier ^m   Benitez, Javier ^m   van Asperen, Christi J ^a   Devilee, Peter ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Istituto Europeo di Oncologia ^*  (Italy)

ⁱ MAYO CLINIC   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m Structural Biology and Biocomputing Programme   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; UNCLASSIFIED DRUG; X RAY REPAIR CROSS COMPLEMENTING 2 PROTEIN;

ALLELE; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ALLELES; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OPEN READING FRAMES;

EID: 84870256911     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2012-101191     Document Type: Article

References (11)

1. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F Neuhausen SL, John EM, Andrulis IL, Terry MB, Daly M, Buys S, Le Calvez-Kelm F, Lonie A, Pope BJ, Tsimiklis H, Voegele C, Hilbers FM, Hoogerbrugge N, Barroso A, Osorio A, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV, Goldgar DE, Southey MC. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012;90:734-9.
2. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 2012;49:184-6.
3. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
4. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-74.
5. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de SD, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295-305.
6. NHLBI Exome Sequencing Project (ESP). Exome Variant Server. http://evs.gs. washington.edu/EVS/ 2012.
7. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de SA, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van DC, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR. Low-penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
8. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.
9. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
10. Deans B, Griffin CS, Maconochie M, Thacker J. Xrcc2 is required for genetic stability, embryonic neurogenesis and viability in mice. EMBO J 2000;19:6675-85.
11. Deans B, Griffin CS, O'Regan P, Jasin M, Thacker J. Homologous recombination deficiency leads to profound genetic instability in cells derived from Xrcc2-knockout mice. Cancer Res 2003;63:8181-7.